Condition: Advanced Solid Tumor · Sponsor: RemeGen Co., Ltd.
This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.
This description comes directly from the study's public registry record.
Xiaohong Su · +8610-65018841 · na.su@remegen.com
Tianshu Liu, ph.D · +86-21-31587871 · liu.tianshu@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Gansu Wuwei Tumour Hospital | Wuwei, Gansu, China | Recruiting |
| Meizhou People's Hospital | Meizhou, Guangdong, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Nanyang Central Hospital | Nanyang, Henan, China | Recruiting |
| Xinyang Central Hospital | Xinyang, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
| Xuzhou Central Hospital | Xuzhou, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical University | Bengbu, Shandong, China | Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06038396